These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 37993916)
1. Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response. Yang H; Gu X; Fan R; Zhu Q; Zhong S; Wan X; Chen Q; Zhu L; Feng F J Ovarian Res; 2023 Nov; 16(1):223. PubMed ID: 37993916 [TBL] [Abstract][Full Text] [Related]
2. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma. Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X Front Immunol; 2022; 13():923194. PubMed ID: 35935940 [TBL] [Abstract][Full Text] [Related]
4. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
5. Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma. Liu P; Chen R; Zhang X; Fu R; Tao L; Jia W BMC Genomics; 2022 Jan; 23(1):51. PubMed ID: 35026984 [TBL] [Abstract][Full Text] [Related]
6. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy. Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069 [TBL] [Abstract][Full Text] [Related]
7. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725 [TBL] [Abstract][Full Text] [Related]
8. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232 [TBL] [Abstract][Full Text] [Related]
9. The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma. Hwang C; Lee HJ; Na JY; Kim KH; Song YJ; Kim JY; Kim K; Shin DH; Park JY; Kim SY; Lee JH; Choi KU J Ovarian Res; 2023 Jan; 16(1):3. PubMed ID: 36609273 [TBL] [Abstract][Full Text] [Related]
10. Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883 [TBL] [Abstract][Full Text] [Related]
11. Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery. Li S; Zhu Z J Ovarian Res; 2020 Aug; 13(1):91. PubMed ID: 32772926 [TBL] [Abstract][Full Text] [Related]
12. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts. McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642 [TBL] [Abstract][Full Text] [Related]
13. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer]. Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477 [No Abstract] [Full Text] [Related]
14. Impact of Activation of Sznurkowski JJ; Żawrocki A; Krawczyńska N; Bieńkowski M; Wasąg B; Biernat W Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35630004 [No Abstract] [Full Text] [Related]
15. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. McCluggage WG Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of the immune microenvironment in ovarian cancer patients. Yang L; Wang S; Zhang Q; Pan Y; Lv Y; Chen X; Zuo Y; Hao D Mol Omics; 2018 Oct; 14(5):341-351. PubMed ID: 30129640 [TBL] [Abstract][Full Text] [Related]
17. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer. Chen S; Dai X; Gao Y; Shen F; Ding J; Chen Q Sci Rep; 2017 Dec; 7(1):16922. PubMed ID: 29208958 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of prexasertib monotherapy in recurrent Lampert EJ; Cimino-Mathews A; Lee JS; Nair J; Lee MJ; Yuno A; An D; Trepel JB; Ruppin E; Lee JM J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32709712 [TBL] [Abstract][Full Text] [Related]
19. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206 [TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Webb JR; Milne K; Kroeger DR; Nelson BH Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]